Affibody licensee Rallybio reports Phase 1 data showing sustained complement inhibition with RLYB116
Affibody has reported positive Phase 1 data from its licensee [...]
On World Cancer Day (WCD), Affibody highlights its progress in [...]
Affibody has reported positive 16-week data from a global Phase [...]